for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akcea Therapeutics Inc

AKCA.OQ

Latest Trade

18.77USD

Change

0.69(+3.82%)

Volume

15,351

Today's Range

18.13

 - 

18.77

52 Week Range

13.90

 - 

35.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.08
Open
18.34
Volume
15,351
3M AVG Volume
5.79
Today's High
18.77
Today's Low
18.13
52 Week High
35.82
52 Week Low
13.90
Shares Out (MIL)
93.03
Market Cap (MIL)
1,682.03
Forward P/E
-35.98
Dividend (Yield %)
--

Next Event

Akcea Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Akcea Announces Damien Mcdevitt As Interim Chief Executive Officer

Akcea Reports Q2 2019 Results

Akcea Therapeutics Reports Q1 Earnings Per Share $0.34

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akcea Therapeutics Inc

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Industry

Biotechnology & Drugs

Contact Info

22 Boston Wharf Rd Fl 9

+1.617.2070202

http://akceatx.com/

Executive Leadership

Christopher F.O. Gabrieli

Chairman of the Board

Damien McDevitt

Interim Chief Executive Officer, Director

Michael Maclean

Chief Financial Officer

Louis St. L. O'Dea

Chief Medical Officer

Joseph Klein

Director

Key Stats

2.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019(E)

0.3K
EPS (USD)

2017

-3.050

2018

-2.740

2019(E)

-0.503
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.65
Price To Book (MRQ)
4.56
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.35
Return on Equity (TTM)
-34.80

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up